Nature Communications (Sep 2018)
Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination
- Nina M. S. Gustafsson,
- Katarina Färnegårdh,
- Nadilly Bonagas,
- Anna Huguet Ninou,
- Petra Groth,
- Elisee Wiita,
- Mattias Jönsson,
- Kenth Hallberg,
- Jemina Lehto,
- Rosa Pennisi,
- Jessica Martinsson,
- Carina Norström,
- Jessica Hollers,
- Johan Schultz,
- Martin Andersson,
- Natalia Markova,
- Petra Marttila,
- Baek Kim,
- Martin Norin,
- Thomas Olin,
- Thomas Helleday
Affiliations
- Nina M. S. Gustafsson
- Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet
- Katarina Färnegårdh
- Kancera AB, Karolinska Science Park
- Nadilly Bonagas
- Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet
- Anna Huguet Ninou
- Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet
- Petra Groth
- Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet
- Elisee Wiita
- Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet
- Mattias Jönsson
- Kancera AB, Karolinska Science Park
- Kenth Hallberg
- SARomics Biostructures AB
- Jemina Lehto
- Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet
- Rosa Pennisi
- Department of Sciences, Roma Tre University
- Jessica Martinsson
- Sprint Bioscience
- Carina Norström
- Kancera AB, Karolinska Science Park
- Jessica Hollers
- Department of Pediatrics, Emory University School of Medicine
- Johan Schultz
- Kancera AB, Karolinska Science Park
- Martin Andersson
- Sprint Bioscience
- Natalia Markova
- Malvern Instruments
- Petra Marttila
- Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet
- Baek Kim
- Department of Pediatrics, Emory University School of Medicine
- Martin Norin
- Kancera AB, Karolinska Science Park
- Thomas Olin
- Kancera AB, Karolinska Science Park
- Thomas Helleday
- Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet
- DOI
- https://doi.org/10.1038/s41467-018-06287-x
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 16
Abstract
Targeting the glycolytic PFKFB3 enzyme is being studied as a therapeutic strategy against cancer. Here the authors identify PFKFB3 as being involved in homologous recombination (HR) repair of DNA double strand breaks (DSBs) and present a PFKFB3 inhibitor.
